These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23887301)

  • 1. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of 8p is an independent prognostic parameter in prostate cancer.
    Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
    Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
    Grupp K; Ospina-Klinck D; Tsourlakis MC; Koop C; Wilczak W; Adam M; Simon R; Sauter G; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Prostate; 2014 Jul; 74(10):1012-22. PubMed ID: 24789172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
    Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
    Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
    Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
    Burdelski C; Reiswich V; Hube-Magg C; Kluth M; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Huland H; Simon R; Schlomm T; Sauter G; Steurer S
    Clin Cancer Res; 2015 Aug; 21(15):3471-9. PubMed ID: 25925890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.
    Burdelski C; Dieckmann T; Heumann A; Hube-Magg C; Kluth M; Beyer B; Steuber T; Pompe R; Graefen M; Simon R; Minner S; Tsourlakis MC; Koop C; Izbicki J; Sauter G; Krech T; Schlomm T; Wilczak W; Lebok P
    Tumour Biol; 2016 Sep; 37(9):12655-12663. PubMed ID: 27444279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.
    Minner S; Hager D; Steurer S; Höflmayer D; Tsourlakis MC; Möller-Koop C; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Sauter G; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Izbicki J; Burandt E; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Heumann A
    Neoplasia; 2019 Sep; 21(9):872-881. PubMed ID: 31382165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KPNA2/ERG Coexpression is Associated With Early Recurrence in Advanced Prostate Cancers.
    D'Antonio A; Caputo A; Fraggetta F; Pepe P; Insabato L; Barra E; Barresi V; Altieri V; Greco U; Savastano R; Zeppa P
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):62-66. PubMed ID: 31809312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
    Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
    PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
    Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.